NEWTON, Mass., June 28, 2011 /PRNewswire/ — Rcadia Medical
Imaging today announced that the company has been granted four
patents by the U.S. Patent and Trademark Office covering technology
for its COR Analyzer® System. The COR Analyzer performs
fully automatic analysis of Coronary CT Angiography (cCTA) studies
to accelerate emergency department triage of suspected coronary
artery disease (CAD) patients and optimize cardiology and radiology
department workflow. The System is marketed in the U.S. and
distributed through an agreement with Siemens Healthcare.
“The COR Analyzer is a powerful decision support tool which has
shown great potential in clinical trials and routine use to reduce
unnecessary admissions and shorten time to treatment,” said Shai
Levanon, President and CEO of Rcadia. “The patents strengthen the
intellectual property position around this innovative system.”
He noted that the COR Analyzer is the first of a new category
of software applications to broadly enable the use of advanced
imaging technologies in emergency medicine to improve care and
reduce costs.
The four patents broadly cover methods and algorithms for
automated analysis of coronary CT angiography studies and detection
of pathologies in coronary arteries. The patents also cover methods
for results visualization and automatic assessment of study
quality. In addition, the methods are extended to cover the
automatic interpretation of triple rule out studies.
Triage of suspected CAD patients represents a major clinical and
healthcare economic challenge in the U.S. An estimated six
million patients enter the ED in the U.S. each year with chest
pain. Because current diagnostic techniques are often equivocal, an
estimated two million, primarily low risk patients, are admitted to
the hospital for further testing at an annual cost of $10-$13
billion. In an estimated 85 percent of these patients, an acute
coronary event is subsequently ruled out.
‘/>”/>
